Urological cancer, Malmö
461 – 470 of 491
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2002
-
Mark
Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer.
(
- Contribution to journal › Article
- 2001
-
Mark
Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues
(
- Contribution to journal › Article
- 2000
-
Mark
Studies on phenotypic expression patterns of proteases and protease inhibitors in benign compared to malignant prostate tissues
(
- Contribution to journal › Article
-
Mark
Increased presence of cells containing transforming growth factor alpha (TGF-alpha) in ulcerative colitis, both during active inflammation and in remission
(
- Contribution to journal › Article
-
Mark
Expression and characterization of trypsinogen produced in the human male genital tract
(
- Contribution to journal › Article
-
Mark
Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum
(
- Contribution to journal › Article
-
Mark
Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer
(
- Contribution to journal › Article
- 1999
-
Mark
The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer
(
- Contribution to journal › Article
-
Mark
Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy
(
- Contribution to journal › Article
-
Mark
CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk
(
- Contribution to journal › Article